Popular antidepressant recalled for high levels of a potentially cancer-causing chemical

Breckenridge Pharmaceutical has issued a recall for nearly 360,000 bottles of duloxetine, a generic version of the antidepressant Cymbalta, due to the presence of potentially carcinogenic chemicals. The U.S. Food and Drug Administration (FDA) reported that the medication contained elevated levels of nitrosamines, which may increase the risk of cancer over time. This recall underscores the pharmaceutical industry's ongoing struggle with impurity management in generic drug production and the critical role of regulatory oversight in maintaining patient safety.

The recall, which was formally announced by the FDA on June 4, involves approximately 360,000 bottles of duloxetine delayed-release capsules produced by Breckenridge Pharmaceutical. The primary cause for the market withdrawal is the detection of nitrosamines, a class of chemical compounds that are classified as potential human carcinogens when found in high concentrations. This generic medication is widely prescribed for depression and anxiety, making the scale of the recall particularly significant for the retail pharmacy supply chain and patient populations relying on affordable generic alternatives.

The scope of the recall includes both 30-mg and 60-mg sizes of the delayed-release capsules. Specifically, the FDA highlighted that 30-mg capsules belonging to lot code 241180C, which carries an expiration date of April 2027, are among the affected products. While the recall is substantial in volume, it focuses on specific batches that failed to meet safety standards regarding chemical impurities, highlighting the precision required in modern pharmaceutical quality control and batch tracking.

Patients who are currently using the recalled duloxetine are being urged to contact their physicians or pharmacists to discuss alternative treatment options and next steps. Medical experts have issued a stern warning that patients should not discontinue the medication on their own, as stopping an antidepressant abruptly can lead to serious health complications or withdrawal symptoms. This incident reflects a broader trend of nitrosamine-related recalls that have impacted various sectors of the pharmaceutical industry in recent years, necessitating stricter quality control measures for manufacturers to ensure long-term consumer safety.